Workflow
C4 Therapeutics: An Entry Point If There's Ever Going To Be One

Core Viewpoint - C4 Therapeutics (NASDAQ: CCCC) is perceived as undervalued, with the stock being described as "too cheap to ignore" [1] Company Analysis - The author has a PhD in biochemistry and extensive experience in analyzing clinical trials and biotech companies, indicating a strong foundation for evaluating C4 Therapeutics [1] - The focus is on educating investors about the science behind biotech businesses, emphasizing the importance of due diligence in this sector [1] Investment Considerations - There is a potential for the author to initiate a long position in C4 Therapeutics within the next 72 hours, suggesting a positive outlook on the stock [2]